Free Corsodyl® CPD opportunity* on the topic of gum disease
GSK, manufacturers of Corsodyl® have launched a new distance learner for dental professionals on the topic of gum disease.
According to the Delivering Better Oral Health toolkit, maintaining periodontal health and preventing periodontitis should be based on;¹ detecting periodontitis early using the Basic Periodontitis Examination (BPE) and managing the factors that expose patients to a greater risk of the disease, e.g. smoking, diabetes and medications.
The 2009 Adult Dental Health Survey found that only 17% of dentate adults in England, Wales and Northern Ireland had very healthy periodontal tissue and no periodontal disease.² This confirms a need for continued patient education regarding gum health.
The Corsodyl® distance learner module provides training on periodontal disease, the BPE, and patient management to treat and prevent the condition. It is suitable for the whole dental team to use and is available 24 hours a day. On top of this, there is no time limit to complete this module and completion of the module can contribute up to 1.5 hours towards your verifiable CPD.
Visit www.gsk-dentalprofessionals.co.uk to complete the module now!
*which can contribute up to 1.5 hours towards your verifiable CPD
References:
Delivering Better Oral Health. An evidence-based toolkit for prevention. 3rd edition. The Department of Health, 2009
Executive summary: Adult Dental Health Survey 2009. The Health and Social Care Information Centre, 2011 (Ed I O’Sullivan)
Trade marks are owned by or licensed to the GSK group of companies.
Product Information
Corsodyl Mint Mouthwash, Corsodyl Original Mouthwash, Corsodyl 0.2% Mouthwash (Alcohol Free)
Active Ingredient: Chlorhexidine digluconate Indications: Plaque inhibition; gingivitis; maintenance of oral hygiene; post periodontal surgery or treatment; aphthous ulceration; oral candida. Legal category: GSL. Licence Holder: GlaxoSmithKline Consumer Healthcare, Brentford, TW8 9GS, U.K.
Information about this product, including adverse reactions, precautions, contra-indications and method of use can be found at:
https://www.medicines.org.uk/emc/medicine/21648
About the author
Related Posts
Comments
By accepting you will be accessing a service provided by a third-party external to https://www.gdpuk.com/
GDPUK Ltd announces sale of intellectual property to leading publisher Cogora Group
GDPUK Ltd today announces the sale of its intellectual property assets to Cogora Group, one of the UK's leading publishers of healthcare brands, events and educational platforms.
The decision to sell GDPUK’s intellectual property forms part of a considered transition to ensure the long‑term stewardship and development of the brand and associated assets. Cogora brings a wealth of experience and expertise to support the continued evolution of the dentistry brand within its wide portfolio of market-leading healthcare publications. Its award-winning titles include Pulse, a long‑standing and widely recognised source of political news and clinical education for GPs, Nursing in Practice, Management in Practice, The Pharmacist, Pulse PCN and Healthcare Leader, as well as two secondary care publications – Hospital Healthcare Europe and Hospital Pharmacy Europe. The purchase will cement Cogora as the biggest publisher of primary care titles in the UK and allow it to bring its expertise in providing news, analysis, opinion and groundbreaking stories to GDPUK, as well as continue giving dentists and dental staff a voice through its website.
“After careful consideration, we believe that Cogora is well positioned to take GDPUK’s intellectual property forward,” said Tony Jacobs, founder, editor and publisher of GDPUK.com . “This transaction provides continuity for the professional community associated with GDPUK and creates opportunities for future growth under experienced ownership.”
Tony will continue involvement in GDPUK on a consulting basis.
GDPUK Ltd has worked to ensure an orderly transfer of the intellectual property and wishes Cogora every success in its future development.